Accession Number : ADB250354


Title :   Identification of Novel Targets of the Human Cell Cycle Regulatory Protein Cdc34


Descriptive Note : Annual summary 1 Jul 96-30 Jun 99


Corporate Author : BAYLOR COLL OF MEDICINE HOUSTON TX


Personal Author(s) : Pati, Debananda


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/b250354.pdf


Report Date : Jul 1999


Pagination or Media Count : 40


Abstract : The goal of this project was to understand the role of human ubiquitin-conjugating enzyme (UBC), hCdc34 in normal and malignant mammary cells. To elucidate the mode of hCdc34 action in human cells, we used a genetic assay called two-hybrid cloning to identify proteins that interact with hCdc34, screening 1.5 million human cDNAs. Thirty cDNA clones found to be active in this assay were isolated and analyzed. Four of these clones are previously known regulators of meiosis and spermatogenesis, including two that belong to the bZIP family of transcriptional repressors, and one has distinct role in sister chromatid cohesion and DNA double strand break repair. We have authenticated the two-hybrid interactions by clearly demonstrating the targeting of three repressors of cAMP-induced transcription, hICERII gamma, hATF5 and CREM beta by hCdc34 and a structurally similar UBC enzyme, hRad6B for ubiquitin-proteasome mediated proteolysis (Pati et. al., 1999, Mol Cell Biol 19: 5001-13). This study provides novel information that stability of specific mammalian transcription factors is the result of complex targeting by multiple UBC enzymes, and may have far reaching physiologic implications in cAMP-inducible gene regulation which governs diverse cellular processes including cell cycle and oncogenesis. These results will also be critical to designing new therapeutic strategies that could modulate the activity of the Cdc34 enzyme to prevent the growth and/or genesis of breast tumor.


Descriptors :   *BREAST CANCER , ENZYMES , PROTEINS


Subject Categories : Genetic Engineering and Molecular Biology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE